Physician profile
Jason Engel
NPI 1104404789
$2,708.16
in general payments reported to CMS, 2019-2025
45 companies · $2,045 in 2025
The $2,045 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $20.35 · 2024: $642 · 2025: $2,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,708.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $190.95 | 2025 | Reblozyl, Breyanzi, Opdivo |
| Incyte Corporation | $171.74 | 2025 | Jakafi, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $154.89 | 2024-2025 | Calquence, Imfinzi, Lynparza |
| Janssen Biotech, INC. | $150.99 | 2025 | Rybrevant, Tecvayli, Erleada |
| Merck Sharp & Dohme LLC | $137.20 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Takeda Pharmaceuticals U.S.A., INC. | $128.14 | 2023-2025 | Iclusig, Gattex, Fruzaqla |
| Novartis Pharmaceuticals Corporation | $120.61 | 2025 | |
| Stemline Therapeutics INC. | $89.81 | 2024-2025 | Orserdu |
| Alexion Pharmaceuticals, INC. | $87.49 | 2024-2025 | Ultomiris |
| Bioventus LLC | $83.33 | 2025 | Stimrouter Implantable Kit |
| Genentech USA, INC. | $83.00 | 2025 | Venclexta, Polivy |
| Rigel Pharmaceuticals, INC. | $74.79 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Taiho Oncology, INC. | $70.98 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $64.90 | 2025 | Opdivo |
| Alnylam Pharmaceuticals INC. | $64.26 | 2024-2025 | Givlaari |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $63.46 | 2024-2025 | Xpovio |
| Regeneron Healthcare Solutions, INC. | $62.05 | 2025 | Libtayo, Lynozyfic |
| Beone Medicines USA, INC. | $61.92 | 2025 | Tevimbra, Brukinsa |
| Jazz Pharmaceuticals INC. | $60.38 | 2024-2025 | |
| Pfizer INC. | $57.39 | 2024-2025 | |
| Daiichi Sankyo INC. | $50.70 | 2025 | Enhertu, Vanflyta |
| Sobi, INC | $43.64 | 2024-2025 | |
| Novo Nordisk INC | $43.28 | 2025 | |
| Genzyme Corporation | $43.20 | 2024-2025 | |
| Glaxosmithkline, LLC. | $40.55 | 2024-2025 | Zejula, Jemperli |
| Astellas Pharma US INC | $39.74 | 2024-2025 | Xospata, Vyloy |
| Servier Pharmaceuticals LLC | $39.33 | 2025 | |
| Abbvie INC. | $38.86 | 2025 | |
| Acrotech Biopharma INC. | $37.87 | 2024-2025 | Beleodaq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.91 | 2025 | |
| Immunocore Limited | $34.84 | 2025 | Kimmtrak |
| Geron Corporation | $27.01 | 2025 | Rytelo |
| Pharmaessentia USA Corporation | $25.13 | 2024 | Besremi |
| Hema Biologics, LLC | $23.57 | 2024 | Sevenfact |
| Sanofi-Aventis U.S. LLC | $21.40 | 2025 | |
| Exelixis INC. | $20.86 | 2025 | Cabometyx |
| Adc Therapeutics America, INC. | $19.42 | 2025 | |
| Adaptive Biotechnologies Corporation | $19.31 | 2025 | Clonoseq |
| Kedrion Biopharma, INC. | $19.18 | 2024 | Gammaked, Kedrab, Albuked |
| Emmaus Medical, INC. | $18.46 | 2025 | Endari |
| Bayer Healthcare Pharmaceuticals INC. | $18.37 | 2025 | |
| Lilly USA, LLC | $17.93 | 2024 | Jaypirca, Verzenio |
| Aveo Pharmaceuticals, INC. | $17.21 | 2025 | |
| Array Biopharma INC | $17.13 | 2024 | Tukysa, Mektovi, Braftovi |
| Genmab U.S., INC. | $15.98 | 2024 | Epkinly |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Engel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.